TX-MOBIL-1/FORZA-MTRSPRT
25.7.2024 23:52:29 CEST | Business Wire | Press release
Today, the Mobil 1 brand, the world's leading synthetic engine oil, announced its expanded collaboration with Forza Motorsport, the best-selling and most-awarded racing video game franchise, in which gamers and race fans around the world will be able to compete against professional motorsports drivers such as racing legend Tony Stewart and recent INDY NXT winner Jamie Chadwick. Beginning July 25, 2024, gamers and motorsports fans will have the unique opportunity to compete against these drivers on Maple Valley, a United States-themed, Mobil 1-branded, in-game track. Additional professional race car drivers will be announced later this year for gamers to compete against in upcoming Legend vs. Leaderboard Rival Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725776163/en/
Motorsports icons including Tony Stewart and Jamie Chadwick to race gamers in-game and on-track in Legend vs. Leaderboard Rival Events. (Graphic: Business Wire)
The collaboration continues the celebration of the Mobil 1 brand’s 50th anniversary through exclusive branded content, a chance to win incredible prizes, and the opportunity to beat iconic motorsports driver’s timed laps on the 4.81km virtual course. The Forza Motorsport collaboration marks the Mobil 1 brand’s largest campaign in the video game entertainment space and celebrates both the Mobil 1 team’s 50-year legacy and its longstanding passion for racing.
Kicking off the Legend vs. Leaderboard Rival Events is racing legend Tony Stewart, an American motorsports icon. From July 25 to August 7, 2024, gamers will have the chance to try to beat Stewart’s time on the Maple Valley virtual racetrack. Fans can also look forward to exclusive content on Mobil 1 Racing social media channels – part of a Legend vs. Leaderboard Rival Events social media series – showcasing Stewart setting his time to beat while driving a classic 1969 Ford Mustang Boss 302. New celebrity drivers will be featured in the content series throughout the remainder of 2024. Each month, a new legendary driver will take on the Maple Valley track, providing ongoing challenges, new prizes, and additional content for audiences to enjoy.
“We are thrilled to bring this iconic collaboration to life with Forza Motorsport to continue the celebration of the Mobil 1 brand's historic 50th anniversary,” said Laura Bustard, Global Brand Manager, on behalf of the Mobil 1 team. “This collaboration signifies our continued commitment to innovation and excellence in motorsports while also showcasing our passion for racing beyond a physical racetrack but increasingly in the virtual world. We are proud to have created a dynamic and immersive experience for gamers and race fans that allows us to celebrate our legacy, and we cannot wait to see fans share in the excitement by racing against a variety of professional motorsports drivers.”
Later this summer, the next Legends vs. Leaderboard Rivals Event series will take place and feature British racing driver Jamie Chadwick. From August 29 through September 11, 2024, gamers will have the opportunity to race against the rising motorsports star. Chadwick will be racing a 1967 Corvette as she invites the global Forza Motorsport audience to join her in-game for the chance to beat her timed lap.
Forza Motorsport, created by Turn 10 Studios and Xbox Game Studios, continues to be one of the premier racing games by giving players an opportunity to participate in racing events around a variety of both real and fictional tracks – including some of their favorite tracks – available in-game. As the Mobil 1 brand continues to grow within the gaming space and curate incredible experiences for driving enthusiasts, the Forza Motorsport relationship serves as a key milestone to reach new audiences and provide unique virtual automotive experiences – all while sharing its love of driving at a global level.
The Legends vs. Leaderboard Rival Events will kick off on July 25 and run through December 11, 2024 with five different events for gamers and race fans to participate in.
To stay up to date and learn more about this collaboration, visit https://promotions.mobil.com/offers/Mobil1Gaming-forza. Also, stay tuned for driver announcements and exclusive content on @Mobil1Racing on Instagram and X.
About Mobil 1
For 50 years, the Mobil 1 brand has been trusted by drivers to help keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1 products, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725776163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom